Edgewise Therapeutics, Inc.
EWTX
Pozycja w akcjach
#4059
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Cena akcji
$37.15
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$4.00B
Zmiana (1 dzień)
-2.75%
Zmiana (1 rok)
146.68%
Kraj
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Kategoria
Healthcare
EPS dla Edgewise Therapeutics, Inc. (EWTX)
EPS na dzień June 2026 TTM: $-1.85
Według najnowszych raportów finansowych i ceny akcji firmy Edgewise Therapeutics, Inc., obecny EPS (TTM) wynosi $-1.85. Na koniec roku 2023 firma miała EPS w wysokości $-1.57, wzrost w porównaniu do do EPS z roku 2022, który wynosił $-1.26.
Historia EPS dla Edgewise Therapeutics, Inc. od 2019 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-1.85 | 27.59% |
| 2024 | $-1.45 | -7.64% |
| 2023 | $-1.57 | 24.60% |
| 2022 | $-1.26 | 46.51% |
| 2021 | $-0.86 | 145.71% |
| 2020 | $-0.35 | 84.21% |
| 2019 | $-0.19 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -1,036.22% |
US
|
|
| $-7.98 | 331.35% |
US
|
|
| $-5.29 | 185.95% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,599.46% |
NL
|
